

## **IDEA Annual Review**

## Key Conclusions 2016


March 6<sup>th</sup>, 2017

IDEA Annual Review – March 6, 2017

## IDEA Annual Review 2016 Key conclusions



- Both for haptens and pre/prohaptens, QRA2 is sufficiently advanced to now be assessed for its effectiveness and reliability.
- The proposed surveillance work, building on existing systems and ensuring adequate quality control elements, finds support. Inclusion of new fragrance materials could contribute to a better assessment of QRA2 effectiveness.
- Recognizing that AAT methodologies for potency assessment of fragrance ingredients are in their early stages, the group supports IDEA's role with focus on multi-stakeholder dialogue, network building and facilitation.
- For slowly oxidizing pre-haptens, the analytical program should contribute to understanding consumer exposure. In combination with additional tools (e.g. ROAT) it should help better interpret clinical data.
- As part of future work, many existing fragrance ingredients need to be assessed with QRA2.
- A pragmatic, lean and agile approach to future work including surveillance is desirable.



## Thank you for your attention

